Trial Profile

Ph II Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head and Neck Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gefitinib (Primary) ; Carboplatin; Fluorouracil; Hydroxycarbamide; Paclitaxel
Indications Head and neck cancer; Nasopharyngeal cancer; Squamous cell cancer
Focus Therapeutic Use

18 May 2020 Status changed from active, no longer recruiting to completed.
08 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
08 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jul 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com